New targeted radiation approach tackles Hard-to-Treat prostate cancer

NCT ID NCT06379217

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-stage trial tests a type of targeted radiation therapy for metastatic neuroendocrine prostate cancer, a rare and aggressive form of the disease. The treatment uses imaging to find specific markers on tumor cells and then delivers radiation directly to those cells. The study involves 31 participants and aims to see if the treatment is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: targeted radiation therapy (radioligand therapy) using PSMA, SSTR2, or GRPR targeting
What this could lead to: If successful, this could lead to a new treatment option for a rare and aggressive form of prostate cancer that currently has few effective therapies.
What could go wrong: This is a very early (phase 1) and small study (31 people), so safety and effectiveness are not yet established. The treatment may not shrink tumors or improve survival, and side effects from targeted radiation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates